In short
Podcast Summary: CNBC's "Fast Money" Episode from 9/17/25
Episode Overview In this episode, hosted by Brian Sullivan in place of Melissa Lee, the discussion revolves around significant market movements following a Federal Reserve interest rate cut, recent developments in the pharmaceutical sector, and notable retail activity. The episode features insights from a roundtable of expert traders and includes a special guest appearance by Richard Fisher, former Dallas Federal Reserve president.
Key Topics Discussed
- Federal Reserve and Market Response
- Interest Rate Cut: The Federal Reserve announced a 25 basis point rate cut, which was largely anticipated by the market.
- Market Reactions:
- The Dow reached new highs, while small caps performed well.
- Nasdaq did not perform strongly, indicating volatility in tech stocks.
- Bond Market: The 10-year yield remained steady, with no significant decrease in mortgage rates anticipated.
- Diverging Opinions within the Fed:
- Different views on future cuts were expressed, with some members advocating for aggressive cuts while others preferred more restraint.
- Concerns about Inflation: Discussions highlighted the Fed's dual mandate of managing inflation and employment, with implications for future economic directions.
- Key Insights from Richard Fisher
- Fisher discussed the balancing act the Fed must perform between controlling inflation and supporting employment levels.
- He expressed skepticism about the influence of new board member Stephen Myron, emphasizing the importance of economic logic over political pressure in Federal Reserve decisions.
- Pharmaceutical Developments
- The episode examined the competitive landscape between Eli Lilly and Novo Nordisk in the obesity medication market.
- Eli Lilly: Reported a 12% weight loss in trial participants, with mixed reactions from investors.
- Novo Nordisk: Announced a higher weight loss percentage (16%), raising questions about market positioning and pricing strategies as they prepare for upcoming drug launches.
- Discussion focused on the future potential of these medications and the importance of physician endorsements in determining which drug becomes the preferred choice.
- Retail Sector Highlights
- Retail stocks reached their highest levels in years, with Walmart receiving particular attention after a price target increase from Bank of America.
- Walmart: Positioned as a leader in the agentic AI commerce space, showcasing its ability to expand margins amidst competitive pressures.
- Costco: Noted for maintaining a high membership renewal rate, indicating strong customer loyalty.
Key Takeaways
- Market Sentiment: The reaction to the Fed's rate cut was mixed, with some sectors thriving while tech remained cautious.
- Pharma Competition: Eli Lilly and Novo Nordisk are in a tightly contested race in the obesity drug market, with long-term implications for investors.
- Retail Resilience: The retail sector shows signs of recovery, driven by strong performances from major players like Walmart and Costco.
Final Thoughts The episode encapsulates a pivotal moment in the financial landscape, with traders and economists navigating the complexities of Fed policy, competitive market dynamics in pharmaceuticals, and robust retail growth. The insights provided by the expert panel offer valuable perspectives for investors looking to understand current market trends and future implications.
For more details on this episode, visit [CNBC Fast Money](http://fastmoney.cnbc.com).
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:00Hi, it's Melissa. Before we jump into today's show, I've got something exciting to share. On December 11th, we are hosting a special edition of Fast Money Live, trading the holidays right here at the NASDAQ market site. You get to watch a live taping of Fast Money, meet and interact with the traders, and, of course, celebrate the holiday season with us. It's stocks and cheers in the heart of the city, Times Square in December. You will not want to miss this. Tickets are available now at CNBCEvents.com slash Fast Money. Live from the NASDAQ market site right here in the heart of New York City's Times Square, this is Fast Money.
0:33Here's what's on tap. The Fed in focus. Jerome Powell and company delivering on a rate cut. Stocks mostly shrugging it off, but one group had a nice pop. We're going to dissect what may be in store for the rest of the year. Lilly's next move. They want to sell you an obesity pill. Will investors buy in? Plus, the retail rally. Lyft scoring a big win in the rideshare battle. and why the chart master says it is time right now to sell maybe the biggest China name of all. Hi, everybody. I am Brian Sullivan in for Melissa Lee tonight. Coming to you live from the Studio B at the NASDAQ. And on your desk tonight, Mr.
1:11Tim Seymour, Dan Nathan. What's up, Sally? Steve Grasso. How are you doing, Tim? And Michael Cantopoulos. He is the deputy chief investment officer at Richard Bernstein Advisors. Also, have Carter Worth coming up in just a minute. Tim looks a little underdressed in that picture, huh? How so? Well, you guys are just. I don't know what's going on. This kid can't go off the rails. We're not like after 20 years of change in the uniform tonight, all right? Sandy Cannell, let's make he wants blood pressure down. All right. Let us start with where else the Fed and stocks. The Dow making a new high. Small caps got a little bit bigger.
1:49The Nasdaq, though, did not play a starring role here on Broadway. Some tech stocks pulled back. In bonds, don't get your hopes up that mortgage rates are going to come crashing down anytime soon. The 10-year yield ending pretty much where it began the day. Oil and gold both lower as the U.S. dollar actually did something it hasn't done a lot of. It actually went higher against most major currencies. All this, of course, after the Federal Reserve did what pretty much everybody expected. It cut its overnight lending rate by one quarter of one percent. Question, of course, now is what now? Newly appointed Governor Stephen Myron, the only board member voting for a full one-half percentage point cut.
2:31Let's get now some of the headlines of the man who is right there in the room where it happened. Steve Leisman with more. Steve. Thanks, Brian, and thanks for not breaking into song. The Fed gave the market almost exactly what it wanted, a 25-base point rate cut and a forecast for two more. But it also introduced some risk into the outlook. Look, there was an expected dovish dissent for a 50 base point cut by Fed Governor Stephen Meyer, but also widespread disagreement on the committee over the right path for rates. Ordinarily, when the labor market is weak, inflation is low. And when the labor market is really strong, that's when you have to be careful about inflation.
3:08So we have a situation where we have two sided risk. And that means there's no risk free path. And so it's quite a different difficult situation for policymakers. And it's not at all surprising to me that you have a range of views. A huge range of views. In fact, one person on the committee in their forecast did not want to cut. Six wanted no more cuts. Two wanted one more cut. Nine wanted two more cuts this year. Three, by the way, was the average. One person who we think is Stephen Myron wanted five more cuts this year. That forecast for deep cuts, by the way, called outrageous by Jeffrey Gunlock, but could be a sign of things to come.
3:50According to Joe Buswelles, he said, given the coming changes to Federal Reserve personnel next year, we urge all to take this forecast with more than a grain of salt and would strongly suggest the Federal Reserve is moving in a direction where it will tolerate inflation well above target. Gunlock himself was concerned about negative interest rates. Futures markets trading, though, with confidence that there will be at least two cuts this year, maybe more confidence than Powell expressed. The key to the immediate outlook may be in the statement. It said that downside risks for employment have increased.
4:18As long as that's the case, the Fed may be cutting rates until inflation and employment risks are believed to be balanced. Brian? Any talk about this so-called, you know, third agenda that they may have about keeping interest rates stabilized for a long period? kind of adding that third leg to the Fed's stool along with the job market and overall inflation? So just to be clear, Brian, I've always known that was there, but it was never an aim of policy. The policy has always been focused on getting essentially inflation to target and doing so with maximum or the best you could do when it comes to employment.
4:58The idea of stable interest has always been in the Federal Reserve Act, but it's never been a focus of policy. I don't hear it right now, Brian, as a focus of policy, but I do hear people like Gunlak talking about this concern. I'll read you this quote that he said here real quickly where he said, I think the job interview that is for chair will be what will you do what I tell you to do? And if the answer is no, I think you're not going to be Fed chair. So that's one of the concerns I will point out, though, and I think this is worth pointing out. The best way to secure or to improve your position for Fed chair would have been to dissent for a 50.
5:35Chris Waller and Mickey Bowman, both Fed chair candidates, did not do that today. Well said. And a lot of drama, not just around interest rates, but inside the Fed and the statement as well. Steve Leesman, we're glad you're there. Steve, thank you very much. All right, guys, let's go around the table, talk about sort of put policy to action. Tim, your take on the Fed today. It was a hawkish cut. There was no drama. In fact, that's what we wanted. It's what the market wanted. It's what the institution of the Federal Reserve wanted. And I think if you look at what the market had priced in, it had absolutely priced in 25.
6:09But it was it was it was inching for more than two rest of year and one in 26. I don't think it's a disaster. The downgrade of the labor market also no real surprise here. But when you hear that from the Fed and what we all say all the time is that a growth scare is something that would be a lot more powerful than the Fed not doing another 25 or 50 basis points. They didn't say that. I'm kind of happy we got this one out of the way, because I actually think this was as uneventful outside of what it is for the institution of the Federal Reserve. And I thought, you know, Bowman and Waller did a great job.
6:42Even with the Myron call for half-point cut? What did you expect? I mean, I don't I I expected that. are expected an outlier, and that's what we got. Everyone else voted in line. Yeah, I think those two folks that dissented in the last meeting, I think it's pretty interesting that they didn't dissent this time. It was such a big deal. We hadn't seen two dissenters in a very long time. That was kind of the narrative when you looked at that last meeting. So at the end of the day, I think they kind of did what they did or needed to do. They signaled, you know, what is going to be the case. I don't think there was too much expectations that there would be that much more than 75 basis points this year.
7:13I'm actually a little surprised at just two expected 25 basis point cuts next year. But they seem pretty much in the camp that their dual mandate is fairly balanced right here. And, you know, I just think of this. The stock market basically closed flat. You know, the 10-year yield closed flat. I mean, this is the sort of market we're going to be in. I think that PCE that's coming up is at the end of next week. I mean, might that be something that folks are, you know, concerned with? We saw the inflation readings over the last two weeks. We just didn't see any stock market volatility in around those sorts of things.
7:44Yeah, but we have an S &P, Dan, that's up, I think, and don't at me as Guy would say, 10 % over the last three months. So was it a buy the rumor? We also had gold. You know, gold has gone up 11 % in that same time period. When's the last time we could ever remember that gold has gone up in tune with a huge rip in the stock market? So there is some stuff going on under the surface. Yeah, and rates did come down ahead of this, to your point. We saw yields come down basically 10 % in the last two months from the 30-year down to the two-year. So I think there was a lot of pre-loading, front-loading on this.
8:17I think there's going to be more 25 basis point cuts. Three in a row. Maybe we'll get that. But just remember, May— I think that many— There's only seven people called for no cut. Yeah, things change. Expectations change on a dime. And let's remember, May 2026, Powell's not going to be there. So I think the more you get closer to that or head into that date of May, the more dovish the Fed actually becomes. And those dissenters probably get louder. Yeah, because, Michael, I'm going to say something now that's going to offend approximately 99 % of our audience. Which isn't something not terribly new.
8:52It's not everybody. Which is that if you're running a hedge fund or you're Goldman Sachs or any of your clients, if you wait until the Fed actually makes a rate call to say, oh, let's now buy stocks, you're done. You're fired. You're finished. Wall Street did not wait. For weeks, they've been buying bonds, bringing yields down, buying gold, buying stocks. Yeah, I'm going to be a little bit of the party pooper here. You know, every time the Fed cuts rates because of poor growth, you don't basically have a durable rally until they get well below neutral and you're actually stimulative. So unless you think they are now below neutral and that they're only cutting because of some sort of immaculate disinflation, you shouldn't actually be buying today's cut.
9:35No one really small caps a little bit. Well, not only that. Well, you have to think about the rally that we've seen has been anticipation of this cut. Right. So so it's already happened. The rally because of the cut has happened. In my view, you know, Chair Powell indicated that he's caught between a rock and a hard place. And I think that was actually a pretty bearish message. He basically said, listen, guys, this is an insurance cut. This is not the start of a new cutting cycle because we can't because we're worried about inflation. And that's not necessarily positive. So I want to that's fascinating.
10:06And so does that mean that as of Jackson Hole, it would sell the market? Because ultimately what you're saying is any type of a cut environment, and that's where the Fed really pivoted. Leave the politics aside. Let's talk about the data, which is I know what you're doing. And I hear you historically. But again, if you think about all the accommodation and where rates were as a function of COVID and nothing else, and hanging on too long that these cuts are in line with the history you're talking about. You know, I don't think so, because I don't think the Fed is actually restrictive. Right. If you look at financial conditions, they're incredibly easy.
10:39And so, you know, I just disagree with the idea of the Fed being restrictive at the moment. And, you know, unless you get, listen, and it is possible, Tim, if you get falling inflation without growth rolling over, it's a boon to the market. We know that, right? But what's the likelihood that you're not going to get inflation or serious margin compression from tariffs? I think that's very, very low. Let's stay right there because I will, and we got a great guest, a perfect guest actually to answer this because I'm going to say something too. And this is one of the reporters, I can't remember who, followed up with Jerome Powell and said, I'm confused.
11:13I was listening to Jerome Powell. I was a little confused. He didn't sound as focused as maybe I would have liked him to be. But it doesn't matter what I think. Let's bring in Richard Fisher, former Dallas Federal Reserve president, also a CBC contributor, a senior advisor to Jeffries. Richard, good to see you. Do you feel like Powell may be a little confused? And maybe it's not his fault. If so, you could say, no, he's not. But when you've got AI out there, you've got this weird thing happening with jobs. And to Tim's point, you're coming off of four or five years where everything was kind of muddled up by COVID.
11:50I think we could forgive him if he is. Or am I wrong? Was he completely lucid today? Look, I don't like the word confused. I thought he was quite honest. It's not clear in terms of the balance of risk, which he articulated. We have some opposite forces acting here. Obviously, inflation is running closer to the 3 % level. And by the way, if that's the case, you should always have a positive real return. Otherwise, you hamper capital formation for businesses. So they're close to that presently as inflation is running at the same time. And I thought he was pretty articulate on this, which is the reason that we have weak employment statistics, in addition to the revisions and all that kind of stuff, is because of, he didn't say it directly, but because of the fiscal policy and because of immigration policy.
12:44So I didn't hear any confusion. I just heard a great articulation. I want to say one thing, though. Now, as far as Bowman is concerned and Waller, I was rather proud of them because they stuck to their sense of economic logic. And clearly, it's not just voting for 50 base points this time, but for five cuts. It's very clear that Mr. Myron will only do what the president wants. And the best part about that, in my view, having been on that committee for 10 years, the way you win an argument is through persuasion. and economic logic and presenting the data as you see it, he's having no influence whatsoever.
13:27And I think that's a good thing. We'll see how this evolves. He didn't have a chance to read the materials before the meeting. And we'll have to see when the transcript finally comes out how he behaved. And I assume that was civil. But the nice thing is he had no influence. He had no influence, no influence on the argument. And that's pretty clear. And projecting five cuts going forward, he's way out left field. Or should I say way out in right field in the case of this administration? I see what you did there. You said a lot. That's why we love having you on, Richard, by the way. So let's try to unpack this one by one.
14:04Okay. Stephen Myron also, by the way, has kind of a dual role in the White House and in the Fed, which I don't think if we've seen it before, it's probably like in the 20s or 30s. And you'll forgive me for my lack of deep Fed history. You can comment on that. But what I'll say and what I meant by Jerome Powell at the top, Richard, is that this is the first cut that we've had with the PCE and other inflationary measures as high as they are, I think. And Tim can talk to speak for himself why they called this a, quote, hawkish cut. Well, again, they do have a dual mandate. Although every president, I don't care if it's Donald Trump or Democrat or Republican in history, has always emphasized the employment data.
14:52That's where their votes come from. That's why they worry about employment. It's perfectly understandable. And every Fed chairman, even though you have a dual mandate of the modern system, has to worry about inflation slash deflation. And I think finding that balance is a very difficult one. But I will not be the least bit surprised if the White House is critical of this decision because the president's worried about the employment situation. And he also, I think, and this is highly opinionated, forgive me, but he wants to have a scapegoat. So his average voter, 60 % of his vote came from people without either high school education or less.
15:32So that demographic here, when he says, I want rates cut, I understand his politics. And that is those people listening to him who are a little more economically distressed right now than the rest of the 1%, et cetera, hear that and think, ah, my credit card payment, my auto payments, my home payments will go down. As we all know, it doesn't work that way. That's not related to Fed funds. It's related to where the 10-year is trading or where you are further out in the EO curve. So I understand the president's position. I understand the politics of it. The important thing is that the central bank not hew to that, as Myron appears to be doing, but instead that they do things as objectively as the central bank should do.
16:15And let's hope they get it. Richard, we brought you on for that opinion. So we're glad that you expressed it, Richard. No, seriously, Richard Fisher, thank you. These are interesting times at the Fed. No, we don't want to. That's why you're a contributor. We actually legally can't. No, Richard, thanks for coming, Richard Fisher. Thank you very much. Those points, well taken. And I think his point at the end was kind of taken as well, Tim, because the bond market didn't move today. The Fed can say what banks can lend at tomorrow. But I think the bond market's going to have a say at what happens three, six months, years from now.
16:54Right. And the bond market, if it was really worried about the Fed as an institution, might have started to talk a little bit more today. And the long end rates might sell off. And because I can't do a better job on the the economic story and inside of the Fed than Richard Fisher. I'm just going to give you my market perspective on this. This was a mildly hawkish cut, which gives you the reaction it had today. Of course, gold sold off today. Of course, the dollar strengthened today. I think the dollar continues to weaken. If the trend is anything close to what Michael is saying, the dollar is going to weaken, and that's going to continue to be good for not only investing internationally and the emerging markets, which are alive and well and have a lot more intrinsic growth than we have here.
17:32But I think mega cap tech is going to have its best quarter of the year in the fourth quarter because I don't see anything that stops that. So today was a breath for the market. And I think it was an exciting day for the Federal Reserve because it is nice to see they are still in line. Richard talked about jobs numbers. Jobs numbers have been abysmal. And it's not just he stated immigration. If you go back, there was a print of revisions of almost a million jobs. It was never as strong as the Biden administration said it was. Not that they lied, but it wasn't that strong. So you have immigration, you have issues, but we revised it by 900 ,000.
18:11I think that revision was for the first until 25. No, it was. It was. It was. It was. Yeah. It was. It was. It was six months or four months of the presidency. Yeah, it was backdated. It was all the government jobs that were added. It was not. It was it was a buy. We don't need to talk about the Biden. No, no, no. My point is the economy and the jobs market is weaker than we all think it is for various reasons. You've heard that. So we've heard that, but that's why they should be cutting. That's why they should be cutting 50 basis points versus 25. So, you know, he mentioned GDP, 1.5 percent, down from 2.8 percent last year.
18:49We know the average of jobs over the last, you know, let's call it 12 months, that's been weakening fairly dramatically. And so what Mr. Fisher just said from a political standpoint, it makes perfect sense. We're starting to even see, you know, he gave a stat about folks who don't have college degrees. Every day you're reading a new story about the unemployment rate for kids who are graduating from college. It's been a difficult situation. I think Fed Chair Powell even spoke to that sort of today. So you have, you know, weakening jobs market. You have weakening GDP year over year. and you have a scenario where, you know, it's like, I don't know.
19:24I mean, like, that was a risk management cut. That's what he said they're going to do, and they're going to sit here, and they're going to wait. CPI last year was 3.4 % on average. We have it not that much lower right now. The irony of this whole thing is that, you know, the administration wants to cut front-end rates, and they're talking about the multiplier effect and housing affordability and all this. And what happens if you cut a lot into the greatest economy ever? Long-term rates skyrocket. Hold on, hold on. Let's not forget, they cut rates 75 basis points last year. When we tripped the SOM rule.
19:55Yeah, but which four people in America had ever heard of until they did that. Me and I. No, yeah, maybe around this day, but you get my point. I think that's what frustrates some people is that we got three cuts last year. Now we get sort of one cut, but yet the economy arguably was better last year than it is right now. Well, if you look at the macro data in August of last year, July and August of last year, it was objectively worse. You look at PMIs well below 50. Which is why they rushed to 50. Exactly, which is why they rushed to 50. And the committee thought inflation was trending lower because tariffs weren't an issue.
20:33Remember, if we didn't have tariffs right now, the Fed would be seeing weak job numbers and no risk to inflation. And they might be cutting more. But because of tariffs, they're wary of inflation. They don't want to cut as much. All right. It's a good discussion there. Big news story, but we're not done on deck. Why news out of Nashville gave a big lift to Lyft. Plus, why Carter Ward says it is time to sell one of China's biggest stocks.
21:09Our Lyft was a big winner today. The ride share company popping 13 percent is partnering with driverless car company Waymo and it's coming to Nashville. In other words, soon, guys, you could have a few drinks in Nash Vegas and then call a Waymo on the Lyft app. Shares at the highest level in three years. Uber, by the way, Tim, falling on the news. Well, I think there has been this whole Waymo and which platform actually might be. And there have been times we've been selling both these names on those days when it seemed as if they weren't going to be the platform from which driverless, whether whether it's Waymo, whether it's Tesla.
21:46I think part of the story in Lyft is also that the company is now got a lot more credibility with the street. The analyst community probably took 15 months to get used to a new management team. The former management team did a poor job, had zero credibility with Wall Street. I think you had some insider buying, which is part of the story here. think this is a company that was waiting to kind of normalize. I think it's a bunch of ingredients. You can't tell me that this headline today is the reason why the stock before today was up 65 percent since a month ago. It's there and they're going into driverless autonomous, as you just stated.
22:22Their international expansion, the acquisition of FreeNow app. All of this is heavy growth. I think the stock probably can cross over the$30 range. Then it gets a little sticky. What do we learn today, though? You make a deal that doesn't involve human beings, your stock pops. Well, let's be clear. I'm being serious. This is not, Sully, this is not them going into autonomous vehicles. This is them doing a deal to find the logistics for one way or another. You know, Uber has done this with Waymo also. So it's just telling you that Waymo is in the capber seat. Waymo can go to any of these folks and say, we want to do this.
22:57Waymo knows that a robotaxi from Tesla sometime in the future, we just don't know when, let's take the over on that, is going to be there. So the more entrenched that they can be, the more markets they can be and using the different, like, it's sort of a situation. We've been talking about this for a while since Lyft was the L in your Bland. Yeah, Blysep. But it was a Bland acronym. No, but the point here is that this thing had a$5 billion enterprise value like a year ago, you know, and they turn profitable and they're growing double digits and, you know, that sort of thing. And people have just kind of left them out a little bit.
23:30They're not even in it. You've been in a Waymo? I have. Dude, I was in it yesterday. I took four of them in LA. Dude, how do I know? I'm not tracking your movements, dude. It is. I didn't say that you knew one way or another. I'm just telling you that I did it. Dude, I was in one year. I took 10 Waymo rides in Los Angeles the last three days. It's amazing, isn't it? It is literally you're in the future. It's pretty fun. But the question is, we've been talking about, do they scale? Okay, like you look at these nice cars and they have all this hardware on them and the software that goes into it, that sort of thing.
23:55So I don't know if they do. RoboTaxi, I think that the Tesla valuation has a lot to do with that. But listen, I think Lyft is in a great spot. I think one of these networks probably buys them at some point. The stock trades at 1.3 times sales. I don't think it's expensive, but I sold 30 calls out to December because the stock's gone from 13 to 23 in three weeks. And I can roll up and out if some great stuff's happening. There's a lot of momentum in the stock. Take advantage of it. All right. Good discussion on Lyft and Dan's travel. Coming up, we're going to go from driverless cars to chicken fried steak.
Read the full transcript
24:31You don't even know what that is, Seymour. Is that Crocker Barrel? Crocker Barrel is on the move today. We're going to tell you why and what's expected from the quarter of the stock. Down big. You're watching Fast Money Live with the NASDAQ Market Site in Times Square. We are back right after this.
24:54All right. Welcome or welcome back, everybody. If you're just joining us, stocks, they closed mixed this after the Federal Reserve did deliver what everybody and their mother and their mother's mother expected. And that was a quarter point rate cut. The Dow did rise. It's up 260 points. The S &P and the Nasdaq were down. Small caps actually doing pretty well in the market today. All right. So what happened when the market closed? Well, you got some stocks that are on the move. Cracker Barrel right now down 9%. They missed earnings expectations. Obviously, a lot of drama lately around the old Cracker Barrel.
25:28StubHub adding to a recent flurry of technology-based IPOs. However, shares the online ticket seller notching a rare loss in its debut. That stock down about 6.3 % from their IPO. Clearly, bankers hoping it would go a little bit different than that. In the meantime, Alibaba continuing its rally today reports that the Chinese e-commerce company signed a major customer for its AI chips. Yes, apparently Alibaba is making AI chips. Shares are up more than 7 % this week. They're trading at nearly four-year highs. However, Chartmaster Carter Worth says it is time to trim your long Alibaba. Carter Worth, welcome.
26:11What are the charts showing? Sure. Yeah, today's note to clients was just simply a follow-up from the August 12th note making the case to play, as seen in this chart, for a move out of the apex of that formation, meaning a coiled spring. The new iteration, if we were to pull it up, the stock, of course, has moved out of that formation. Now, do you sell at all? I don't think so. The second chart depicts the conclusion of that standoff up and out. But 36 percent in five weeks, a lot more than the K-Web or the FXI. My thought was trim a third to a half and then let the balance ride or sell calls.
26:50The 180s for October going for five bucks allows you to participate for another eight, nine percent and 12 percent if you include the five dollars received. Anyway, a steep, uncorrected day to day, week over week advance. Take some measures. That was the thought. Yeah, and I guess those measures would be to trim that position. Chartmaster Carter Worth, thank you very much. Dan Nathan, thoughts on Alibaba? Carter does amazing work here. He does. The shirt, he looks very relaxed. He's amazing. The two areas that I would focus on, first on technicals, the last two times over the last year we've seen these sorts of parabolic moves, it's kind of retraced maybe 30%, 35 % of those in each indication.
27:29So, you know, his point about this thing breaking out from a technical perspective, I think to chase it here, you're probably making a mistake. And then the other one is like, if you just think about how Chinese stocks have acted or the sentiment around China relative to these trade talks or whatever, it's just a really interesting backdrop, I think. You know, when you think about our companies being able to get this probably what looks like a sweetheart deal with TikTok into this sort of negotiation, I just think that this is something to kind of pay attention to. But it could be somewhat artificial.
28:00It could be somewhat of a sell the news once we have a framework. All right, Michael, no, you're not an individual stocks guy. China broadly has been red hot the last couple of months. Yeah, it sure has. And I would wonder how much of the move in Baba overall and the market in general is just a function of, you know, growth momentum and how that's really sort of percolating throughout markets in general, whether that be, you know, the MAG7 here in the U.S. or amongst China markets, K-Web, M-Chai, et cetera, in China. And if you look at it, the reality is you have a lot of bubbling up of earnings growth internationally.
28:32Tim mentioned that earlier. I believe. But China's not one of the places where you're seeing that. Chinese earnings growth is actually declining rather than accelerating. So I think much of what we see in China is more about momentum, more about momentum growth. And if there's a reason for that to stop, then I think the house of cards starts to fall. Well, we'll see. I'll tell you what, if you're talking about that and if Carter worth, Tim, is right, they'll say the exodus is here. The happy ones. I don't know who you just quoted, man, but it was good. How about Riley by the hoop? All right. Coming up, the latest drug trial results on Eli Lilly's weight loss pill and how they're hoping it is going to tip the scales in the weight loss race.
29:12We're back after this. Put out the fire.
29:21All right, welcome back. Novo Nordisk stock, high right now, just under 3%. reports that its higher-dose weight loss pill did help patients lose nearly 17 % of their body weight at 64 weeks. Now, this coming on the heels of detailed results from the first obesity trial of Eli Lilly's weight loss pill. Stock reaction, though, a little bit muted. Stock actually closed down 0.6%. Let's get more on what we know with Angelica Peebles. Angelica. Hey, Brian. Well, there's a lot of data today to get through, But first, let's start with Lilly. So Lilly's pill helping people lose about 12 % of their body weight after 72 weeks.
30:01And that's in line with what we previously heard from Lilly. And of course, that headline number initially disappointing investors, but doctors today praising the results, saying that this pill could become a first-line treatment for obesity, especially in the primary care setting, where of course many people are getting treated. And one researcher giving possible reasons for the lower-than-expected weight loss. For example, that this trial enrolled more men than usual. and men actually tend to lose less weight than women, believe it or not. And one doctor pushed back on investor criticism that the amount of weight loss here won't be enough.
30:32But just a few minutes ago, Novo saying that its obesity pill helped people lose more than 16 percent of their body weight. And Novo is feeling quite good about these results. I spoke to a Novo executive earlier today and telling me that in their view, this is the first time that we have an oral obesity drug that's similar to the shots in terms of efficacy, tolerability and safety. and also a head-to-head trial today between both of these pills, suggesting that side effects caused more people to stop taking Lilly's pill than Novo's. So that's also something to watch here. Now, for Lilly, the edge really is about the ability to scale its pill and ship it around the world.
31:10So that is one advantage. But there's so much here, and it's just something that we're going to have to watch as these two drugs come to market. Brian. All right, Angelica, thank you very much. All right, let's welcome in our guest, Jared Holes on set. Mizuho Healthcare Strategist. Jared, first, your reaction to Novo, Eli, and anything else you want. And also, it's kind of a little bit in left field, but do we know, a lot of people I talk to on these drugs complain about muscle loss, not fat loss, and then they regain the weight. What do we know about these medications as of now? Well, great to be here.
31:43I think, first of all, both trials seem to be pretty good. Like when you look at them for what they are, to have a daily weight loss pill that's going to produce anywhere between 12%, 15%, 16 % body weight reduction is great. So we have a solution that's going to be in it. A lot of hope for a lot of people who've been struggling. Massive hope. And to me, it's a consumer product. It's going to be very difficult to see this not doing extremely well. Tough to really parse out Novo versus Lilly. We just got the Novo data. It looks great on the surface, but we'll see kind of what the reactions are.
32:14In terms of the muscle loss, I think it's only going to be pertinent for older populations, not as much younger. I think that's really where the concern is. Do we know how long before we are going to actually see these pills on the market? Next year. I think this is going to be a 2026 launch for both Lilly and Novo. So by the time we're sitting here next year, we're going to be in the third full year where the injections are available and the first year where the pills are available. Obesity impacts tens of millions of Americans. Why aren't these stocks reacting even more to this opportunity? I think they're going to.
32:49I think there's going to be a delayed reaction to this novo especially. Well, the market doesn't normally wait. So what's it waiting for? I think the big concern is going to be there are two things the market is questioning. One, pricing. Pricing is going to be less than the injectable. So is it a race to the bottom type situation competitively? And so many other companies in this arena trying to vie for positioning. We don't really know what's going to happen with Amgen, with Roche and a whole other slew of biotech companies here. Well, if that's the case, if you're speaking about the competition as competition, because there has been no competition, then my guess is Lilly, which is not a great stock and a great chart.
33:27It's a great company, but it's been dead money now for a year and a half. It sounds to me like the competitive landscape is about to get a lot worse. And that would be a reason to not buy these stocks. Well, I'm very certain that even over the next two or three years, this is still a two-player market. That all the concerns around the competitive entrance and what's happening in large-cap pharma and biotech are existential longer-term risks because you've got every single player trying to get into the market. This is the biggest therapeutic category by far. So I think over the near term, I feel fine about it.
34:01Long-term, we'll see how this stuff shakes out. Jared, when you look at the two, you said before it's hard to parse out who's going to be better in the long run. Why is that? When I look at Lilly stock, everyone sort of funnels into that name. And on either chart, I don't find anything really exciting to buy on either chart. But when you look out on it, why is it so hard for the analyst community to decide on who's going to be the winner? Well, because the data, like today is kind of metaphorical, right? We had Lilly data in the morning. After the close, you've got Novo. They're going to continue to innovate around each other.
34:33So it's this game of leapfrog and perpetuity, very difficult to kind of ascertain who the winner is on any particular day. So for now, I think Lilly on the injectable side is better. But now with this Wegovi data for Novo on the oral side hitting after the close, it seems like that race might be narrowing a little bit. I would imagine, Jared, please correct me if I'm wrong. The winner is not going to be decided respectfully by Wall Street. It's going to be decided by doctors. Which one do they prescribe? And by insurance companies. By insurance companies. Because if the insurance company says this one's covered, that one's not, this one's going to win.
35:08I agree. Do you have any visibility or clarity into those things? Well, we don't really know what's going to happen with the orals. My guess is that the pricing for these pills is going to be half of what the injectables are, maybe even a little bit less. And we've seen what Novo and CVS have already done in terms of getting that relationship together, driving down the cost to increase volume. That'll continue to happen. But anybody got a take on either of these stocks or any of the weight? Go ahead. I mean, it just seems to me, and as someone that's long Novo over the last, I don't know, three, four months, and the Novo underperformance has been largely been based upon slight percentage differences in terms of body weight loss and tolerability, which is so qualitative, I think.
35:51I realize you take conditions and you try to attach data forms to them. But it just seems to me, as Jared said, and he also said when we were talking on the commercial break, I mean, we're talking about weight loss drugs. These guys are all bragging, by the way, what restaurants they go to in L.A. It was it was anyway, it was a different you didn't see that, folks. But but the point is that my figure. Well, you know, the point is that is that really for most people, that delta on the percentage weight loss and the tolerability enough to have seen Novo Nordis underperform Eli Lilly by 70 percent or so in the last 18 months.
36:25I don't think so, and that's part of the reason why I'm Long Novo. Fair enough. Listen, stocks come from 90 to 58, up a little bit the last couple of weeks. So we'll see if that trend will continue. Jared Holtz, thank you very much. All right, coming up, call it meta madness. Mark Zuckerberg set to take the stage at the company's Connect Conference. What can you expect to hear? How might it impact the stock? Why am I asking so many questions to myself? We're going to a short break. We're back right after this.
37:10Mark Zuckerberg's keynote at the MetaConnect conference, just a couple of hours away. I know you all can't wait. An AI-powered smart glass is expected to take center stage. Julia Boorstin is there. She's got some detail she's able to. I know you know more than you can say, Julia. Well, I'm here at Meta headquarters in Menlo Park. And in just a few hours, we're expecting Mark Zuckerberg to unveil a new version of Meta's AI glasses. These are codenamed Hypernova, and they're expected to be smart glasses that include a display inside the glasses. They're expected to cost around$800, which would include a wristband to control the device with hand gestures.
37:55Now, all of this will build on Meta's AI-powered Ray-Ban smart glasses, which it first launched in 2023. And these new devices are expected to be a step closer to the fully augmented reality glasses called Orion, which Mark Zuckerberg previewed a year ago. This is all part of Meta's increasing focus on hardware. Zuckerberg has emphasized that he believes that glasses, which integrate with Meta AI are the way that people interact with AI in the future. The glasses come from the Reality Labs division, which also includes VR headsets. And this is a division that has lost more than$70 billion since late 2020.
38:32But Zuckerberg says this is a long-term investment. The new version of the glasses come as Meta faces criticism from Congress and whistleblowers about its AI chatbots and the harmful effects of VR and children. We'll be talking about all of Meta's AI announcements in a first on CNBC interview. That's going to be tomorrow morning in Money Movers with Meta's chief product officer, Chris Cox. Brian, back over to you. All right, Julia Borson. Julia, thank you very much. Dan, a take on Meta. Listen, these guys have been early in this kind of stylistic sort of brand. The deal that they did with Ray-Ban, I have a pair of them.
39:07I think they're pretty cool. They're a$300 sort of thing. They don't do a whole heck of a lot. What they're talking about, this next-gen one, it's$800,$900. That's a tougher, you know, sort of price point. Well, it better do something. Well, and it will. It's just not going to do things that most consumers need, right, like now. So you have to be like kind of a gadget guy or gal to really care about those things. And, you know, Julia just mentioned Orion. This is the thing that they introduced last year. They introduced it for availability three years from then. You know what I mean? Like who the heck knows where this stuff is going to be.
39:35What they make off of these glasses and the ones that are coming is like a rounding error on the revenue. So at least it's kind of demonstrating some sort of ability to have some real-world AI in a physical sense. Yeah, I'm old enough to remember Google Glass. It was ahead of its time, by the way. It was, but it didn't do anything. It ultimately went away. I think it will eventually get there. The problem is, does the spend reap the reward eventually? And these guys, to Dan's point, have spent a ton of money. They were there early, but they're spending$60 to$65 billion. And Julia said they've lost since 2020$70 billion.
40:07Now, it's a long-term investment. They're the pioneers or one of the pioneers there. But we have to see when all of this stuff actually pays off. Well, this is one of the problems with these big mega cap tech companies in general. They used to be so attractive because they were asset light. And now essentially they're asset heavy. Reminds you of an oil company who has to constantly dig for wells. That's what this whole entire race with AI and now the metaverse, et cetera, et cetera, really looks like to me. Metaverse, that's going to be it. That's buying fake land next to Snoop Dogg. Just trust me on this one, Michael.
40:39All right, coming up, retail rising, consumer stocks hitting their highest level in years. The names that are leading the charge on that Red Hot segment next.
40:54All right, pretty positive day for the retail S &P ETF, hitting its highest level since January of 2022, a.k.a. a three-and-a-half-year high. One big winner, Walmart hit an intraday record. Bank of America bumping its 12-month price target on Walmart to$125 a share from$120. That implies about$20 more bucks for about 18 % of upside, saying the company is poised to be a leader in the agentic AI commerce space. What does that mean? I have no idea. Tim Seymour, you have a hot take on Walmart? I do. I do. And I think if you want to know why retail did so well and the XRT, or not the XRT, but other retail ETFs, it's because Walmart is probably 12 % to 15 % of it.
41:37and that kind of a move. But the heavyweights have had a pretty good run. The story around Walmart really is margin expansion, even at a time when people may or may not be concerned about some of the margin within the grocery business and some other places where they've been able to really extract a lot. I'm a long-term holder of Walmart. I don't like the valuation, but it's been very impressive how this stock has kept with market forces and continues to trade at a multiple that's probably 10 turns where it's 10-year averages. Yeah, and if you look at the investment, They've touched everything on digital, on commercial, on AI, as you said, the agentic force behind them.
42:11But if you look at Costco as well, Costco still has a 90 percent, above 90 percent renewal rate on their membership. Stock has lagged Walmart, but I put those in the same bucket where I think that's going to be a win. But Walmart's putting out advertising technology, too. Oh, OK. Well, they got that going for them. That's huge. I mean, Amazon has been a huge boon for us. Really high margin. It's great for their mix shift in North America. I mean, listen, the agentic stuff for Walmart, for a lot of these big retailers that have a huge logistical network, right, they're dealing with all these obviously millions and millions of employees, of suppliers, of customers, all this sort of stuff.
42:43It's going to be useful. All right. Up next, it is your final trades.
42:55Michael Cantopoulos, kickoff final trades. I think you're going to have a broadening of the market. The best way to trade that is an equal weight S &P. Tim. Michael, thank you for joining us. Brian, thank you for joining us. Citibank, thank you for going higher. Banks continue. Money Center banks like today's tape. Damn, Sully, you're the man. If you're going to broaden out this market here, Walmart probably breaks out. Steve, rates are going lower. Gold, Ethereum, Bitcoin, all crypto. There you go. I loved it. And we saw you on Power Lunch earlier today. Thank you for schlepping. You were there as well.
43:28I was there as well. Thanks for having me. Guys, we'll see you tomorrow. I'll actually be back tomorrow night. Thanks, everybody, for watching. Mac starts right now. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.
43:59Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
